Benign prostatic hyperplasia (BPH) is one of the most common urologic conditions affecting men as they age, with nearly 50% of men over 50 experiencing symptoms. Despite its prevalence, treatment ...

Teleflex Incorporated announced the presentation of multiple clinical studies at the 2025 American Urological Association Annual Meeting in Las Vegas, highlighting advancements in treatments for ...

Profound Medical Corp. (NASDAQ:PROF) is one of the best Canadian stocks with huge upside potential. On June 10, Profound Medical announced the successful completion of the first commercial benign ...

NEW BERN, N.C. (WNCT) — The Urology team at CarolinaEast Health System announced they are offering A quablation therapy and have completed their 100th treatment. A quablation therapy treats the lower ...

DEAR DR. ROACH: I have benign prostatic hyperplasia (BPH), and I am taking tamsulosin daily. It works and helps with my daily urination. How long should I continue to take it? Are there any related ...

DUBLIN, Aug. 25, 2025 /PRNewswire/ -- ProVerum Limited, the developer of the ProVee® System for BPH, a minimally invasive solution for treating benign prostatic hyperplasia (BPH), announced today the ...

Men aged 50 and above are most commonly affected. (Getty Images) This common condition affects up to three million people in the UK each year – but chances are, you've not heard of it. Benign ...

In a trial, the newly approval urethral stent provided significant and durable relief of BPH-related LUTS over 12 months. The FDA has approved the ProVee® System for treatment of benign prostatic ...

Drug therapy for BPH can be categorized into two groups: agents that interfere with testosterone's stimulatory effect on prostate enlargement and agents that relax prostatic smooth muscle. Of the ...